105 related articles for article (PubMed ID: 30743222)
1. Effect of
Azorín-Vega E; Aranda-Lara L; Torres-García E; Santiago-Bañuelos JA
Appl Radiat Isot; 2019 Apr; 146():24-28. PubMed ID: 30743222
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the radiation absorbed dose produced by
Azorín-Vega E; Rojas-Calderón E; Ferro-Flores G; Aranda-Lara L; Jiménez-Mancilla N; Nava-Cabrera MA
Appl Radiat Isot; 2019 Apr; 146():66-71. PubMed ID: 30753987
[TBL] [Abstract][Full Text] [Related]
3.
Santos-Cuevas C; Ferro-Flores G; García-Pérez FO; Jiménez-Mancilla N; Ramírez-Nava G; Ocampo-García B; Luna-Gutiérrez M; Azorín-Vega E; Davanzo J; Soldevilla-Gallardo I
Contrast Media Mol Imaging; 2018; 2018():5247153. PubMed ID: 30534027
[TBL] [Abstract][Full Text] [Related]
4. Toxicity Assessment of [
Hernández-Jiménez T; Cruz-Nova P; Ancira-Cortez A; Gibbens-Bandala B; Lara-Almazán N; Ocampo-García B; Santos-Cuevas C; Morales-Avila E; Ferro-Flores G
Nanomaterials (Basel); 2022 Nov; 12(23):. PubMed ID: 36500804
[TBL] [Abstract][Full Text] [Related]
5. Comparison between
Nava-Cabrera M; Azorín-Vega E; Oros-Pantoja R; Aranda-Lara L
Appl Radiat Isot; 2021 Oct; 176():109898. PubMed ID: 34418726
[TBL] [Abstract][Full Text] [Related]
6. Clinical translation of a PSMA inhibitor for
Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
8. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
Graf F; Fahrer J; Maus S; Morgenstern A; Bruchertseifer F; Venkatachalam S; Fottner C; Weber MM; Huelsenbeck J; Schreckenberger M; Kaina B; Miederer M
PLoS One; 2014; 9(2):e88239. PubMed ID: 24516620
[TBL] [Abstract][Full Text] [Related]
9. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M
J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the relative biological effectiveness (RBE) of the Lu-DOTA-iPSMA177 radiopharmaceutical.
de la Fuente-Mendoza JE; Azorín-Vega EP; Mendoza-Nava HJ; Rodríguez-Martínez G; Rodríguez-Dorantes M
Appl Radiat Isot; 2023 Dec; 202():111065. PubMed ID: 37879244
[TBL] [Abstract][Full Text] [Related]
12. Lutetium-177 Labeled Therapeutics: ¹⁷⁷Lu-PSMA is Set to Redefine Prostate Cancer Treatment.
Pillai AM; Knapp FF
Curr Radiopharm; 2016; 9(1):6-7. PubMed ID: 26655262
[No Abstract] [Full Text] [Related]
13. Imaging DNA damage response by γH2AX
O'Neill E; Mosley M; Cornelissen B
Theranostics; 2023; 13(4):1302-1310. PubMed ID: 36923536
[No Abstract] [Full Text] [Related]
14. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
15. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
[TBL] [Abstract][Full Text] [Related]
16. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
17. Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing
Ahmadzadehfar H; Essler M
J Nucl Med; 2018 Jul; 59(7):1033-1034. PubMed ID: 29653975
[No Abstract] [Full Text] [Related]
18. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of dose dependent cytotoxic activity in SW480 colon cancer cells by ¹⁷⁷Lu-labeled siRNA targeting IGF-1R.
Fathi M; Taghikhani M; Ghannadi-Maragheh M; Yavari K
Nucl Med Biol; 2013 May; 40(4):529-36. PubMed ID: 23618769
[TBL] [Abstract][Full Text] [Related]
20. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
Lindenblatt D; Terraneo N; Pellegrini G; Cohrs S; Spycher PR; Vukovic D; Béhé M; Schibli R; Grünberg J
BMC Cancer; 2018 Sep; 18(1):922. PubMed ID: 30253737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]